In this issue of GOLD, we reveal the pharmaceutical industry’s key news stories from the past few months, covering the latest COVID-19 vaccine developments, FDA and European Commission approvals, and major collaborations.
'The 2021 Access to Medicine Index' is published, with GSK ranked in first place
Novavax’s COVID-19 vaccine shows 89% efficacy in UK Phase 3 trial
GSK and CureVac partner to develop next generation mRNA COVID-19 vaccines
The European Commission purchases 150 million doses of Moderna’s COVID-19 vaccine
Bayer announce their collaboration with UK-based Exscientia to accelerate the potential of AI in cardiovascular and oncology drug discovery.
Merck & Co. places an offer to acquire Pandion Therapeutics in $1.85 billion deal
Boehringer Ingelheim and Gubra partner to identify peptides to treat obesity
HIV infections among gay and bisexual men in the UK are reported to have fallen by 71%, following the launch of PrEP, a pill that prevents HIV infection.
Novartis signs initial agreement to manufacture CureVac’s COVID-19 vaccine
Roche launches SARS-CoV-2 variant test to monitor COVID-19 mutations
Takeda and Evotec form alliance for strategic RNA targeting drug discovery and development
FDA approves BMS and bluebird bio’s Abecma, the first cell-based gene therapy for patients with multiple myeloma
Johnson & Johnson announces agreement with African Union for ≤400 million doses of its COVID-19 vaccine
The European Commission approve Roche’s Evrysdi, the first at-home treatment for spinal muscular atrophy